{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076768","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.434011+00:00","generated_at":"2026-05-15T23:46:45.101408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance","bullets":["Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.","GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.","Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.","Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.","Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076768","json":"https://secwatch.observer/filing/0001193125-26-076768.json","markdown":"https://secwatch.observer/filing/0001193125-26-076768.md","text":"https://secwatch.observer/filing/0001193125-26-076768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/0001193125-26-076768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/d106442d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:46:45.101408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}